Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics

For the quarter ended September 2025, Astrazeneca (AZN) reported revenue of $15.19 billion, up 12% over the same period last year. EPS came in at $1.19, compared to $1.04 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $14.87 billion, representing a surprise of +2.13%. The company delivered an EPS surprise of +4.39%, with the consensus EPS estimate being $1.14.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:BioPharmaceuticals- R&I- Symbicort- U.S.: $305 million compared to the $302.37 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.BioPharmaceuticals- R&I- Fasenra- Europe: $122 million versus $118.21 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +19.6% change.Oncology- Europe: $1.28 billion versus the three-analyst average estimate of $1.22 billion. The reported number represents a year-over-year change of +24.4%.Oncology- Enhertu- Established RoW: $21 million versus the three-analyst average estimate of $23.89 million. The reported number represents a year-over-year change of +31.3%.BioPharmaceuticals- R&I- Symbicort- World: $742 million versus the three-analyst average estimate of $707 million. The reported number represents a year-over-year change of +5.3%.BioPharmaceuticals- R&I- Pulmicort- World: $93 million versus the three-analyst average estimate of $98.65 million. The reported number represents a year-over-year change of -32.6%.BioPharmaceuticals- CVRM- Crestor- World: $305 million versus the three-analyst average estimate of $320.61 million. The reported number represents a year-over-year change of +0.3%.BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World: $160 million compared to the $142.46 million average estimate based on three analysts. The reported number represents a change of +6.7% year over year.Oncology- Tagrisso- World: $1.86 billion compared to the $1.85 billion average estimate based on three analysts. The reported number represents a change of +11.4% year over year.BioPharmaceuticals- V&I- Synagis- World: $58 million versus $69.33 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -37.6% change.BioPharmaceuticals- R&I- Fasenra- World: $530 million versus the three-analyst average estimate of $498.02 million. The reported number represents a year-over-year change of +21.6%.BioPharmaceuticals- CVRM- Brilinta- World: $146 million compared to the $170.12 million average estimate based on three analysts. The reported number represents a change of -55.4% year over year.View all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have returned -5% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks